On January 1st 2011 Act on the Reform of the Market for Medicinal Products (AMNOG) came into force in Germany. The aim of AMNOG is to curb the rapidly rising expenditure for pharmaceutical products by the statutory health insurance funds.
Since the introduction of AMNOG, more than 100 IQWiG recommendations and G-BA decisions on the early benefit assessment have been published. In various assessments, the IQWiG recommendation and the related G-BA decision differed in terms of decision argumentation and actual result.
In this study, these differences were systematically analyzed in order to draw conclusions for future proceedings and optimization of the process.
Download the poster: Vollmer_et_al._IQWiG_vs_G-BA_ISPOR_2015